# Janssen Research & Development, LLC: Phase 3 study closed enrollment, 743 enrolled (Multiple Myeloma)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy |
| NCT ID | NCT04923893 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Multiple Myeloma |
| Intervention types | drug |
| Target enrollment | 743 |
| Site countries | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, Finland, France, Germany |
| Posted | 2021-06-11 |
| Planned start | 2021-08-19 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-11-03 |
| Last update posted | 2026-11-03 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 743 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04923893). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.